Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIaTrial

In this randomized, double-blind phase 2 trial of TLPO versus TLPLDC, both vaccines were well tolerated. There were no differences in DFS or OS in clinically disease-free melanoma pts receiving TLPO versus TLPLDC vaccines. Given prior efficacy shown with TLPLDC vs placebo, further efficacy testing of both TLPO and TLPLDC vaccines is warranted in a phase 3 trial.